Personalized Medicine in HER2-positive breast cancer

被引：0
|
作者：
Tsurutani, Junji [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw459
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY-8-4
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant Therapy for HER2-Positive Breast Cancer
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [22] Optimizing Treatment of HER2-Positive Breast Cancer
    Gradishar, William J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 649 - 651
  • [23] ADVANCES IN THE MANAGEMENT OF HER2-POSITIVE BREAST CANCER
    Goel, Shom
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 68 - 68
  • [24] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    [J]. CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [25] Hormonotherapy in patients with HER2-positive breast cancer
    Debska, Sylwia
    Potemski, Piotr
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 (06): : 301 - 310
  • [26] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    [J]. LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [27] Management of HER2-Positive Early Breast Cancer
    Steger, Guenther
    Lueftner, Diana
    Stoeger, Herbert
    Thurlimann, Beat
    Untch, Michael
    [J]. BREAST CARE, 2018, 13 (06) : 453 - 455
  • [28] Expert Discussion: HER2-Positive Breast Cancer
    Foukakis, Theodoros
    Matikas, Alexios
    Oikonomidou, Olga
    Andreopoulou, Eleni
    Mavroudis, Dimitris
    [J]. BREAST CARE, 2021, 16 (04) : 422 - 428
  • [29] Treatment Combinations for HER2-Positive Breast Cancer
    Pegram, Mark
    [J]. ONCOLOGY-NEW YORK, 2013, 27 (04): : 258 - +
  • [30] Is there a role for immunotherapy in HER2-positive breast cancer?
    Esther Holgado
    Jose Perez-Garcia
    Maria Gion
    Javier Cortes
    [J]. npj Breast Cancer, 4
12345